We integrated large-scale genomic and plasma proteomic data from over 10,000 individuals to characterize the genetic architecture of host proteins reported to interact with SARS-CoV-2 proteins in cellular assays, or which have been reported to be related to virus entry, the host hyper-immune or procoagulant response, or severity of COVID-19.

We successfully identified 220 independent genetic variants acting in cis for 97 proteins targeted by 106 aptamers ("SOMAmers"; DNA-based protein affinity reagents). Among these 97 proteins, 38 are the targets of existing drugs, including 15 proteins that were previously identified as interacting with structural or non-structural proteins encoded in the SARS-CoV-2 genome and 16 proteins that encode biomarkers related to COVID-19 severity, prognosis, or outcome.

Manhattan plot of cis-associations statistics (encoding gene ±500kb) for 179 proteins. The most significant regional sentinel protein quantitative trait loci (pQTL) acting in cis are annotated by larger dots for 104 unique protein targets (p<5×10-8). Starred genes indicate those targeted by multiple aptamers.

Data access

By using these results in your research, you agree to cite our publication. Our legal notice, data protection statement and data usage agreement apply.

Interactive matrix and annotations for all cis-loci and associated aptamers.
Interactive tables with pGWAS summary statistics for individual SNPs, genes, or genetic regions. Results can be sorted, filtered, and exported.